Rucaparib Prolongs PFS in Ovarian Cancer

Rucaparib Prolongs PFS in Ovarian Cancer - Cancer Therapy Advisor

  The findings suggest that evaluation of tumor LOH can help to identify patients with BRCA wild-type platinum-sensitive ovarian carcinomas who might benefit from treatment with rucaparib.
Reference

1. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Nov 28. doi: 10.1016/S1470-2045(16)30559-9 [Epub ahead of print]